P
Pablo Martinez
Researcher at Hebron University
Publications - 41
Citations - 1248
Pablo Martinez is an academic researcher from Hebron University. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 16, co-authored 40 publications receiving 1079 citations. Previous affiliations of Pablo Martinez include MedImmune & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
Susana Cedres,Susana Cedres,Davis Y. Torrejon,A. Martínez,A. Martínez,Pablo Martinez,Pablo Martinez,Alba Navarro,Esther Zamora,N. Mulet-Margalef,Enriqueta Felip +10 more
TL;DR: Elevated NLR is a predictor of shorter survival in patients with advanced NSCLC and the variation of NLR during the first cycle of treatment predicts survival, and it is found that patients with undifferentiated carcinoma and patients with NLR ≥5 had a worse survival.
Journal ArticleDOI
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
Susana Cedres,Santiago Ponce-Aix,Jon Zugazagoitia,Irene Sansano,A.B. Enguita,Alejandro Navarro-Mendivil,Alex Martinez-Marti,Pablo Martinez,Enriqueta Felip +8 more
TL;DR: PD-L1 is expressed in 20% of patients, associated with no epithelioid histology and poor prognostic in MPM, and these results suggest PD-L 1 warrants further exploration in selecting p for immunotherapy.
Journal ArticleDOI
Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Susana Cedres,I. Nunez,Marina Longo,Pablo Martinez,Eva Checa,Davis Y. Torrejon,Enriqueta Felip +6 more
TL;DR: High levels of tumor markers at baseline are correlated with worse survival in stage III-IV NSCLC patients, and high levels of CEA, CYFRA21-1, and CA125 at baseline were present in adenocarcinoma.
Journal ArticleDOI
Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
Pablo Martinez,Javier Hernández-Losa,M. A. Montero,Susana Cedres,Josep Castellví,Alex Martinez-Marti,Natalia Tallada,Nuria Murtra-Garrell,Alejandro Navarro-Mendivill,Victor Rodriguez-Freixinos,Mercedes Canela,Santiago Ramón y Cajal,Enriqueta Felip +12 more
TL;DR: IHC is a promising method for detecting ALK positive NSCLC patients and has different clinical features and a better outcome than EGFR WT and ALK negative patients.
Journal ArticleDOI
Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)
Susana Cedres,Susana Cedres,Maria Angeles Montero,Pablo Martinez,Pablo Martinez,A. Martinez,V. Rodríguez-Freixinós,Davis Y. Torrejon,Alejandra Gabaldon,M.T. Salcedo,S. Ramón y Cajal,Enriqueta Felip +11 more
TL;DR: This study shows PI3K pathway and downstream proteins in MPM are frequently activated and provides prognostic information and the role of PI3k pathway is worth of prospective validation in future studies on MPM.